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SIGNIFICANCE	STATEMENT	
	
Distal	renal	tubular	acidosis	(dRTA)	is	defined	by	the	inability	of	the	distal	nephron	to	acidify	
the	urine	and	can	be	associated	with	sensorineural	deafness.	About	a	third	of	patients	with	
inherited	 dRTA	 have	 no	 identified	 causative	mutations	 in	 known	 disease	 genes.	 Here	 we	
report	 recessive	mutations	 in	 the	 forkhead	 transcription	 factor	 FOXI1	 as	 a	 novel	 cause	 of	
dRTA	 with	 deafness.	 Our	 findings	 enable	 a	 precise	 diagnosis	 in	 affected	 patients,	 inform	
genetic	counselling,	as	well	as	cascade	screening	and	provide	insight	into	the	transcriptional	
regulation	of	transport	proteins	in	the	distal	nephron	and	inner	ear	by	FOXI1.	
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ABSTRACT		
	
Maintenance	of	 the	composition	of	 inner	ear	 fluid	and	regulation	of	electrolytes	and	acid-
base	homeostasis	 in	the	collecting	duct	system	of	the	kidney	require	an	overlapping	set	of	
membrane	transport	proteins,	regulated	by	the	forkhead	transcription	factor	FOXI1.	In	two	
unrelated	 consanguineous	 families,	 we	 have	 identified	 three	 patients	 with	 previously	
unknown	 homozygous	 missense	 mutations	 in	 FOXI1	 (p.L146F	 and	 p.R213P)	 affecting	 the	
highly-conserved	 DNA-binding	 domain.	 Patients	 presented	 with	 early	 onset	 sensorineural	
deafness	and	distal	renal	tubular	acidosis	(dRTA).	The	mutations	reduce	DNA-binding	affinity	
of	 FOXI1,	 which	 hence	 fails	 to	 adequately	 activate	 genes	 crucial	 for	 normal	 inner	 ear	
function	and	acid-	base	regulation	in	the	kidney.		A	substantial	proportion	of	patients	with	a	
clinical	 diagnosis	 of	 inherited	 dRTA	 have	 no	 identified	 causative	 mutations	 in	 currently	
known	disease	 genes.	Our	data	 suggest	 that	 recessive	mutations	 in	 FOXI1	 can	explain	 the	
disease	in	a	subset	of	these	patients.	
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INTRODUCTION	
	
An	important	homeostatic	function	of	the	kidney	is	the	regulation	of	acid-base	balance.	This	
occurs	in	the	proximal	tubule	via	bicarbonate	reabsorption	and	in	the	collecting	duct	system	
via	proton	secretion.	The	intercalated	cells	of	the	collecting	duct	use	specific	transporters	to	
regulate	 acid-base	 balance	 that	 can	 secrete	 protons	 (type	 A	 intercalated	 cells)	 and	
bicarbonate	(type	B	intercalated	cells).1	Impaired	type	A	intercalated	cell	function	may	lead	
to	 an	 inability	 to	 acidify	 the	 urine	 and	 secrete	 acids,	 with	 consequent	 development	 of	
hyperchloremic	non-anion	gap	metabolic	acidosis.	Mutations	known	to	cause	inherited	dRTA	
have	been	identified	in	transporters	present	in	the	type	A	intercalated	cells	and	include	the	
B1	and	a4	subunits	of	the	vacuolar	H+-ATPase	(V-ATPase),	anion	exchanger	1	(AE1)	and	the	
cytosolic	 carbonic	 anhydrase	 (CAII).2-4	 Interestingly,	mutations	 in	 the	 V-ATPase	 B1	 subunit	
are	 typically	 associated	with	 sensorineural	deafness,	 as	 can	be	 those	 in	a4,2,5	 emphasizing	
functional	 similarities	 between	 the	 epithelium	 of	 the	 inner	 ear	 and	 that	 of	 the	 collecting	
ducts	of	the	kidney.6	This	is	due	to	the	expression	of	a	common	set	of	membrane	transport	
proteins	in	distinct	cell	types	of	the	epithelium	of	the	inner	ear	and	the	renal	collecting	duct.	
Specifically,	Forkhead	related	(FORE)	cells	of	endolymphatic	duct	and	sac	epithelium	of	inner	
ear7	and	intercalated	cells	express	B1	and	a4	subunits	of	the	V-ATPase	proton	pump	and	also	
the	anion-exchange	protein	AE4	and	pendrin.7,8		
	
A	 genetic	 impairment	 of	 urine	 acidification	 can	 be	 associated	 with	 an	 altered	 pH/ionic	
composition	 in	 the	 inner	 ear	 fluid	 and	 hence	 prevent	 proper	 sound	 perception.	 Another	
common	feature	of	these	cell	types	is	that	they	each	express	FOXI1	–	a	transcription	factor	
that	has	been	shown	to	be	crucial	for	regulation	of	AE1,	AE4,	and	the	V-ATPase	subunits	B1,	
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a4,	 A	 and	 E2.8	 Consistent	 with	 this,	 mice	 with	 a	 germline	 deletion	 of	 Foxi1	 display	
sensorineural	 deafness	 and	 dRTA,9,10	 together	 with	 reduced	 expression	 of	 these	 target	
genes.	Although,	a	 family	has	been	 identified,	 in	which	Pendred	syndrome	(PS)	 segregates	
with	 a	 composite	 heterozygous	 genotype	of	 single	 allele	mutations	 in	SLC26A4	 and	FOXI1	
(Yang	et	al.),	yet,	recessive	 loss-of-function	mutations	 in	FOXI1	have	not	been	described	 in	
human	patients.	
	
In	 this	 report,	 we	 describe	 two	 novel	 missense	 mutations	 that	 do	 not	 directly	 affect	
membrane	 transport	 proteins	 but	 rather	 hit	 cell	 function	 at	 the	 transcriptional	 regulatory	
level	–	 in	 that	 they	prevent	 the	 transcription	 factor	FOXI1	 from	binding	 to	 regulatory	DNA	
cis-elements	of	target	gene	promoters.	This	leads	to	a	severely	reduced	activation	of	those	
target	genes,	 including	membrane	transport	proteins,	which	require	FOXI1	 interactions	 for	
proper	expression.	 In	this	way,	these	two	novel	 loss-of-function	mutations	 induce	a	severe	
syndrome	 of	 deafness	 and	 acidosis	 with	 a	 phenotype	 very	 similar	 to	 that	 of	 mice	 that	
altogether	lack	Foxi1	expression.	
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RESULTS	AND	DISCUSSION	
	
CASE	REPORTS	
	
Two	 consanguineous	 kindreds	with	 an	 autosomal	 recessive	 pattern	 of	 distal	 renal	 tubular	
acidosis	and	sensorineural	deafness	were	evaluated	(Fig.	1).	 In	 family	1,	 the	male	proband	
(Patient	1.1)	was	the	eldest	of	3	children,	with	one	affected	sister	 (Patient	1.2;	Fig.	1A).	 In	
family	2,	 the	 female	proband	 (Patient	2.1)	was	 the	only	affected	 family	member	 (Fig.	1B).	
Key	clinical	 features	 in	all	affected	patients	 included	early	onset	sensorineural	hearing	 loss	
requiring	 cochlear	 implants,	 a	 hypokalemic,	 hyperchloremic	 metabolic	 acidosis	 at	
presentation	 with	 inappropriately	 high	 urine	 pH,	 failure-to-thrive,	 and	 bilateral	
nephrocalcinosis	 (Fig	 1E),	 consistent	 with	 dRTA.	 The	 deafness	 was	 profound	 and	 was	
associated	 with	 dilatation	 of	 the	 vestibular	 aqueduct	 (Fig.	 1F	 and	 S3-4).	 The	 dRTA	 was	
associated	with	hypercalciuria	and	nephrocalcinosis	noted	at	presentation,	but	responded	to	
treatment	with	both	alkali	and	potassium	supplements	with	subsequent	catch-up	in	growth	
of	 the	 children.	 In	 addition,	 patients	 1.1	 and	 2.1	 also	 developed	medullary	 cystic	 changes	
within	the	kidney	(Fig.	1E	and	1F).	Clinical	data	are	summarized	in	Table	1.	
	
	
STRUCTURAL	ANALYSIS	OF	MUTATED	FOXI1	PROTEINS	
	
The	 novel	 FOXI1	 homozygous	 missense	 mutations,	 p.L146F	 and	 p.R213P,	 were	 identified	
following	whole	exome	sequencing	 in	the	affected	patients,	with	segregation	of	the	alleles	
from	the	parents	(Fig.	1C	and	1D).	The	mutations	were	not	found	in	the	EXaC	database.	Both	
missense	changes	were	located	within	evolutionary	highly	conserved	residues	of	the	FOXI1	
protein	(Fig.	1G).	Consistent	with	FOX	protein	sequence	alignments	(Fig.	1G	and	Fig.	S1),	 in	
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silico	modelling	 of	 FOXI1,	 using	 the	 crystal	 structure	 of	 rat	 Foxa3,11	 predicted	 that	 FOXI1	
L146	 occupies	 a	 homologous	 position	 to	 L142	 in	 α-helix	 2	 (α2)	 of	 the	 Foxa3	DNA-binding	
domain	 (Fig.	 1H	 and	 1I).	 A	 stabilizing	 interaction	 between	 Foxa3	 and	 its	 cognate	 DNA	 is	
formed	 between	 the	 side-chain	 δ1	 carbon	 atom	of	 L142	 and	 the	 ribose	DNA	 backbone.11	
Identical	results	were	obtained	when	modelling	FOXI1	on	the	structures	of	human	FOXM1,12	
human	 FOXO4,13	 human	 FOXK2,14	 and	 rat	 Foxd3	 15	 (Fig.	 S2),	 with	 similar	 protein-DNA	
interactions	 identified	 for	 the	homologous	 leucine	 residues	 in	 these	 structures.	 The	 FOXI1	
L146F	mutation	was	predicted	 to	disrupt	 this	 stabilizing	protein-DNA	 interaction,	with	 the	
larger	(~30Å3),16	rigid	aromatic	ring	of	phenylalanine	predicted	to	impinge	upon	the	ability	of	
the	recognition	helix	(α3)	to	fully	engage	the	major	groove	of	the	target	DNA	(Fig.	1J).	The	
functional	 importance	 of	 a	 small	 hydrophobic	 residue	 at	 this	 position	 in	 the	 DNA	 binding	
domain	is	highlighted	by	the	almost	complete	conservation	of	a	 leucine	residue	in	the	FOX	
protein	family	(Fig.	S1).	FOXI1	R213	was	predicted	to	occupy	a	homologous	position	to	L209	
in	the	wing	2	domain	of	Foxa3	(Fig.	1K).	Similar	to	Foxa3	L142,	the	side-chain	β-carbon	atom	
of	Foxa3	L209	 interacts	with	 the	 ribose	DNA	backbone.11	Therefore,	we	hypothesized	 that	
FOXI1	R213	also	served	to	stabilize	the	interaction	with	its	target	DNA,	similar	to	the	role	of	
R210,	R211	and	R214	in	Foxa3	(Fig.	1K).	Substitution	of	the	positively	charged	side-chain	of	
arginine	with	proline	(p.R213P)	will	destroy	the	predicted	electrostatic	 interaction	with	the	
DNA,	thereby	disrupting	DNA	binding	(Fig.	1L).	(Further	modeling	information	is	detailed	in	
the	Supplementary	Appendix).	
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FUNCTIONAL	ANALYSIS	OF	MUTATED	FOXI1	PROTEINS	
	
We	 further	 investigated	 the	 functional	 effect	 of	 the	mutations	 in	 vitro.	 First,	we	 assessed	
protein	expression	levels	of	transfected	wild	type	and	the	mutations	p.	L146F	and	p.R213P	of	
FOXI1	 in	 the	 human	 kidney	 cell	 line	 HEK	 293T,	 which	 did	 not	 differ	 (Fig.	 2A).	 Next,	 we	
compared	 trans-activation	 of	 wild	 type	 and	 mutant	 FOXI1,	 using	 previously	 validated	
promoter	constructs,8,10	for	the	human	a4	subunit	of	the	H+-ATPase	(ATP6V0A4),	the	human	
anion-exchange	 protein	 pendrin	 (SLC26A4)	 and	 the	 human	 anion-exchange	 protein	 1	
(AE1/SLC4A1).	 Consistent	 with	 our	 previous	 data,8,10	 wild	 type	 FOXI1	 increased	 reporter	
gene	 activity	 several-fold	 above	 empty	 vector-transfected	 cells,	 while	 the	 p.L146F	 or	
p.R213P	 mutant	 constructs	 show	 significantly	 reduced	 capability	 to	 trans-activate	 these	
promoters	(Fig.	2B).	In	an	electrophoretic	mobility	shift	assay	(EMSA)	we	assessed	binding	of	
wild	 type	and	mutant	FOXI1	proteins	 to	DNA	 in	 the	 form	of	a	canonical	FOXI1	binding	cis-
element.	Wild	 type	FOXI1	bound	 to	 the	oligonucleotide	 (Fig.	2C,	 lane	1),	whereas	no	 such	
interaction	 was	 detected	 for	 the	 p.L146F	 or	 p.R213P	 mutants	 (Fig.	 2	 C,	 lanes	 2	 and	 3,	
respectively).	 Lastly,	 we	 used	 GFP-fusion	 constructs	 to	 determine	 the	 intracellular	
distribution	of	 the	wild	 type	and	mutant	 FOXI1	proteins.	 	Distinct	nuclear	 localization	was	
observed	 for	wild	 type	 and	mutant	 FOXI1	 proteins	 (Fig.	 2D),	 precluding	 defective	 nuclear	
import	 as	 a	 cause	 for	 the	 reduced	 trans-activational	 capacity	 of	 the	 p.L146F	 and	 p.R213P	
mutants.	 A	 morphometric	 analysis	 of	 data	 from	 figure	 2D	 is	 shown	 in	 figure	 S5	 and	 an	
immunochemistry	based	approach	to	intracellular	localization	of	FOXI1	and	the	p.L146F	and	
p.R213P	mutants	are	shown	in	figure	S6.	Taken	together	these	experiments	show	that	these	
mutants	 have	 a	 similar	 intracellular	 distribution	 as	 wt	 FOXI1.	 Our	 patients	 with	 loss-of-
function	mutations	 in	FOXI1	 recapitulate	 the	phenotype	described	 in	 a	mouse	model	 that	
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lacks	 Foxi1	 expression	 with	 early	 onset	 sensorineural	 deafness	 and	 dRTA.7,10	 The	 human	
phenotype	we	report	mimics	 the	renal	 findings	of	patients	with	mutations	 in	 the	B1	or	a4	
subunits	 of	 the	 V-ATPase	 and	 thus,	 FOXI1	 mutations	 are	 important	 in	 the	 differential	
diagnosis	 of	 dRTA.	 The	 phenotypic	 mimicry	 is	 not	 surprising,	 considering	 the	 previously	
reported	important	role	of	Foxi1	in	the	regulation	of	genes	associated	with	dRTA.3,5,10,17	The	
discrepancy	with	respect	to	the	absence	or	later	onset	of	sensorineural	deafness	in	patients	
with	 a4	 or,	 more	 typically,	 B1	 mutations	 is	 likely	 due	 to	 FOXI1	 mutations	 affecting	 the	
regulation	of	several	important	membrane	transporters,	including	those	critical	for	inner	ear	
function,	whereas	isolated	impairment	of	the	a4	subunit	and	B1	accordingly	may	generate	a	
less	severe	phenotype	that	to	some	extent	can	be	tolerated	in	the	ear.	This	emphasizes	the	
difference	 in	 phenotypic	 scope	 between	 a	 mutation	 in	 a	 distinct	 membrane	 transport	
protein	versus	that	of	a	transcription	factor	that	regulates	several	target	genes.		
	
In	murine	 studies,	 in	 the	 intercalated	 cells	 of	 the	 renal	 tubules	 and	 the	 FORE	 cells	 of	 the	
endolymphatic	 duct	 and	 sac	 of	 the	 inner	 ear,	 Foxi1	 regulates	 expression	 of	 B1	 and	 a4	
subunits	of	the	V-ATPase	proton	pump	and	also	the	anion-exchange	proteins	AE1,	AE4,	and	
pendrin.	Without	expression	of	a	functional	Foxi1	protein	there	is	a	failure	to	express	these	
target	genes	and,	as	a	consequence,	this	results	in	severely	impaired	cellular	function,	with	
altered	 ionic/pH	composition	of	 inner	ear	 fluid,	and	a	significantly	 reduced	capacity	of	 the	
kidneys	 to	secrete	an	acid	 load.9,10	The	 inner	ear	phenotype,	seen	 in	mice	 lacking	Foxi1,	 is	
remarkably	similar	to	what	we	show	here	for	one	of	the	probands	(Fig.	1F),	with	dRTA	and	
an	 enlargement	 of	 the	 endolymphatic	 sac	 and	 duct	 resulting	 in	 an	 enlarged	 vestibular	
aqueduct	syndrome	(EVA;	Fig.	S3	and	S4).7,9	
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The	biochemical	analysis	of	mutated	FOXI1	protein	(Fig.	2)	demonstrated	a	severe	reduction	
in	 the	 ability	 to	 interact	 with	 bona	 fide	 FOXI1	 cis-elements	 with	 consequent	 reduced	
expression	 of	 target	 genes.	 This	 is	 consistent	 with	 the	 in	 silico	 analysis	 demonstrating	
impaired	 interactions	of	mutant	FOXI1	with	the	major	groove	of	 target	DNA	(p.L146F)	and	
disturbance	 of	 electrostatic	 interactions	 with	 DNA	 (p.R213P).	 Together	 these	 data	
demonstrate	that,	in	patients	homozygous	for	these	missense	FOXI1	mutations,	there	is	very	
limited	 FOXI1	 DNA-binding	 activity,	 likely	 resulting	 in	 a	 failure	 to	 trans-activate	 a	 set	 of	
membrane	transport	proteins	needed	for	normal	inner	ear	and	kidney	function.		
	
The	patients	in	the	present	study	did	not	show	any	signs	of	goiter,	available	data	on	thyroid	
function	 was	 normal.	 Furthermore,	 we	 demonstrate	 that	 patients	 with	 recessive	 loss-of-
function	mutation	 in	FOXI1	display	dRTA	and	deafness	with	EVA,	suggesting	that	complete	
loss	of	FOXI1	activity	induces	a	unique	and	distinct	phenotype.	In	a	previous	report,	Pendred	
syndrome	 associated	 with	 a	 digenic	 pattern	 of	 inheritance	 in	 which	 a	 composite	
heterozygous	genotype	with	mutations	in	FOXI1	and	SLC26A4	segregates	with	deafness	and	
an	 EVA.18	 In	 this	 patient	 goiter	was	 not	 noted	 and	 the	 contributing	missense	mutation	 in	
FOXI1	was	 located	approximately	50	amino	acids	C-terminally	of	 the	DNA-binding	domain.	
Also	in	this	report,	the	authors	identify	five	patients	with	PS	and	non-syndromic	EVA	with	a	
single	 mutation	 in	 one	 of	 the	 FOXI1	 alleles	 and	 they	 speculate	 that	 perhaps	 also	 single	
mutations	can	cause	PS	and	non-syndromic	EVA.	The	apparent	lack	of	a	clinical	phenotype	in	
the	 parents	 of	 our	 patients	 indicates	 that	 isolated	 heterozygous	 loss	 of	 function	 of	 FOXI1	
does	not	cause	disease,	consistent	with	observations	in	mice	with	a	heterozygous	germ	line	
deletion	 of	 Foxi1,	 who	 also	 have	 no	 phenotype.7,9	 A	 similar	 conclusion	 was	 reached	 in	
patients	 with	 EVA	 and	 heterozygous	 variants	 in	 FOXI1,	 as	 none	 had	 a	 family	 history	 of	
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deafness.18	Based	on	this,	we	find	 it	unlikely	that	a	single	mutation	in	one	FOXI1	allele	will	
cause	disease.	However,	in	combination	with	another	single	allele	mutation	–	for	instance	in	
a	 gene	 that	 regulate	 SLC26A4	 –	 a	 single	 allele	 mutation	 in	 FOXI1	 could	 be	 part	 of	 the	
pathogenetic	mechanism	underlying	PS	with	non-syndromic	EVA.	
	
Of	 interest,	 in	mice	lacking	Foxi1,	males	have	been	shown	to	be	infertile.19	This	 is	due	to	a	
failure	of	clear	cells	in	the	epididymis	to	acidify	the	extracellular	luminal	fluid.	This	leads	to	a	
pathological	 post-testicular	 sperm	 maturation	 and,	 as	 a	 consequence,	 spermatozoa	 from	
Foxi1	 null	 males	 fail	 to	 reach	 the	 female	 genital	 tract	 in	 sufficient	 number	 to	 allow	
fertilization.19	Whether	mutations	in	FOXI1	will	be	associated	with	reduced	male	fertility	also	
in	 man	 remains	 an	 open	 question	 as	 for	 the	 one	 male	 patient	 in	 our	 study	 analysis	 of	
spermatozoa	 function	was	 not	 available.	 FOXI1	 is	 highly	 expressed	 in	 human	 renal	 kidney	
cortex	 (RNA-Seq	 expression	 data	 from	 GTEx	 https://www.gtexportal.org).	 Other	 human	
tissues	 which	 express	 FOXI1	 at	 more	 modest	 levels	 include	 breast	 tissue,	 salivary	 gland,	
prostate	 and	 skin	 (https://www.gtexportal.org/home/gene/ENSG00000168269.7).	 The	
human	 protein	 atlas	 reveals	 high	 levels	 of	 FOXI1	 protein	 expression	 in	 kidney,	 and	 low	
expression	 levels	 in	 nasopharynx,	 bronchus,	 salivary	 gland	 and	 breast	 tissue	
(https://www.proteinatlas.org/ENSG00000168269-FOXI1/tissue).	 Thus,	 it	 is	 possible	 that	
other	 tissues/cell	 types	 than	 those	 reported	 here	 display	 pathological	 phenotypes	 in	
response	to	loss-of-function	mutations	in	FOXI1.	
	
All	three	patients	in	this	study	were	noted	to	have	medullary	renal	cysts,	raising	the	question	
whether	FOXI1	could	also	be	involved	in	cystogenesis.	Yet,	an	association	of	dRTA	with	cysts	
is	well	 recognized:	 in	 our	 own	 cohort	 of	 children	with	dRTA,	 over	 a	 third	developed	 cysts	
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during	childhood.20	Typically,	this	is	ascribed	to	hypokalemia,21	although	other	factors,	such	
as	 hypercalciuria/nephrocalcinosis	 have	 also	 been	 implicated.22	 Observations	 in	 more	
patients	with	dRTA	are	needed	to	better	assess	the	frequency	of	cysts	in	FOXI1-based	dRTA	
compared	to	other	genetic	forms.	
	
Approximately	 a	 third	 of	 patients	 with	 dRTA	 have	 no	 identified	 causative	 mutation	 in	
recognized	 disease	 genes,20,23,24	 and	 thus	 should	 be	 tested	 for	 FOXI1	 mutations	 to	 help	
establish	 a	 precise	 diagnosis	 with	 consequent	 genetic	 counseling	 –	 especially	 in	 cases	
involving	hearing	and	possibly	also	male	fertility	problems.19	
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METHODS		
	
This	 study	 was	 approved	 by	 the	 respective	 institutional	 review	 boards	 (Institute	 of	 Child	
Health/Great	 Ormond	 Street	 Hospital	 Research	 Ethics	 Committee	 05/Q0508/6;	 Newcastle	
and	North	Tyneside	Research	Ethics	Committee	2003/163).		
Parents	 provided	 written	 informed	 consent.	 Three	 subjects	 with	 dRTA	 and	 sensorineural	
deafness,	 without	 identified	 mutations	 in	 known	 disease	 genes	 were	 investigated.	 We	
performed	 whole	 exome	 sequencing	 using	 peripheral	 blood	 DNA	 from	 affected	 family	
members.	Sanger	sequencing	was	used	to	validate	 the	variants	 identified	by	whole	exome	
sequencing	 in	 both	 affected	 children.	 In	 silico	 modelling	 and	 biochemical	 analysis	 was	
performed	with	human	FOXI1	protein	as	a	control	 compared	with	 the	 two	mutated	FOXI1	
proteins.	
	
Whole-exome	sequencing	and	identification	of	FOXI1	sequence	variant	
	
Exome	capture	and	Next-Generation	sequencing	
	
Whole	exome	sequencing	of	affected	Patients	1.1	and	1.2	was	performed	by	GATC	Biotech	
using	the	Illumina	HiSeq-2000	(Illumina	Inc.,	San	Diego,	CA).	The	genomic	DNA	was	captured	
on	 the	 SureSelectXT	 Human	 All	 Exon	 V5	 kit	 (Agilent,	 CA)	 to	 capture	 target	 sequence	 of	
exonic	regions	and	non-coding	RNAs	in	the	human	genome.	The	paired-end	Illumina	libraries	
were	 captured	 in	 solution	 according	 to	 the	 Agilent	 SureSelect	 protocol	 with	 125	 bp	 read	
length.	Perkin	Elmer	(UK)	provided	commercially	available	exome	sequencing	for	Patient	2.1	
(Exome	capture	Agilent	SureSelect	V4;	Read	Length	/	Library	construction:	75-100bp/paired	
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end	 library	 and	 reads;	 Sequence	Coverage:	 ~35X	mean	 coverage;	Detection	of	 sequencing	
fragments	via	the	Illumina	Hiseq2000).	
	
SNP	detection	
	
The	base	quality	of	each	sequence	read	was	inspected	for	low	quality	calls	and	subsequently	
removed	before	proceeding	with	further	processing.	Using	a	sliding	window	approach,	bases	
with	low	quality	were	removed	from	the	3’	and	5’	ends.	Bases	were	removed	if	the	average	
quality	was	below	 the	 threshold	of	 15.	 Finally,	 only	 reads	with	both	 forward,	 and	 reverse	
read,	 were	 used	 for	 the	 next	 analysis	 step.	 Mapping	 to	 the	 reference	 database	 (hg19,	
NCBI37)	 was	 performed	 using	 Burrows-Wheeler	 Alignment	 (BWA)	 method	 with	 default	
parameters.	The	SNP	and	Indel	calling	was	performed	using	GATK’s	UnifiedGenotyper	using	
a	Bayesian	genotype	likelihood	model	to	estimate	simultaneously	the	most	likely	genotypes	
and	allele	frequency	in	a	population	of	N	samples.	Variants	detected	were	annotated	based	
on	 their	 gene	 context	 using	 snpEff.	 The	 total	 reads	 were	 ~145M	with	 the	 percentage	 of	
mapped	 reads	 99%.	 Data	 was	 pipelined	 to	 allow	 Indel	 and	 SNP	 vcf	 files	 to	 be	 generated	
which	were	viewed	using	Ingenuity	Variant	Analysis	software	(Qiagen).	
	
Filtering	 criteria	 used	 for	 single	 nucleotide	 variants	 (SNVs),	 and	 insertion	 and	 deletion	
selection	(Indel).	
	 Family	1	(1.1	and	1.2)	 Family	2	(2.1)	
Number	of	variants		 176834	 80397	
Variants	of	high	confidence	 158256	 79590	
SNVs/Indel	 ≤	 1%	 in	 HapMap18	
and	1000	Genome	database	
	
14363	 6190	
	 15	
Predicted	deleterious	 1076	 2347	
Biological	 context	 (kidney	
disease,	renal	tubular	acidosis)	
217	 8	
Present	 on	 both	 alleles	 in	 all	
affected	individuals*	
1	 1	
	
*Affected	members	after	screening	of	kindred	based	on	clinical	and	biochemical	features.	
	
PCR	primers	used	for	Sanger	sequencing	
FOXI1	 FWD	 CAACCCCTACCTCTGGTTCA	 Exon	1	
FOXI1	 REV	 GGGGAGGAAGGAAGTGAGTC	 Exon	1	
FOXI1	 FWD	 CATCTGTCACCTTGGCTTT	 Exon	2	
FOXI1	 REV	 GGGGAGAAGGAGTTGAAGGT	 Exon	2	
	
For	experimental	details	regarding	in	silico	modelling	and	cell-based	experiments	see	
Supplementary	Appendix.	
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Table	1:	Clinical	and	genetic	characteristics	of	affected	patients		
	
Patient	ID	 1.1
*	 1.2*	 2.1†	
Sex	 Male	 Female	 Female	
Ethnicity	 UAE‡	 UAE‡	 Iraq	
Mutation§	
Nucleotide	 c.436C>T	 c.436C>T	 c.638G>C	
Amino	acid	substitution	 p.Leu146Phe	 p.Leu146Phe	 p.Arg213Pro	
Allele	frequency	
Not	 present	 in	
EXaC∥	 Not	 present	 in	EXaC∥	 Not	 present	 in	EXaC∥	
dRTA	presentation	
Age	at	diagnosis	[years]	 8	 6	 <1	
Symptoms	 Rickets	 Rickets	
Failure-to-thrive,	
rickets	
Weight	[kg]	(SDS¶)	 18	(-2.9)	 16	(-1.9)	 9	(-3.5)	
Height	[cm]	(SDS¶)	 119	(-1.6)	 105	(-2.0)	 83.5	(-2.5)	
Blood	biochemistries	
pH	 7.30	 7.30	 7.30	
tCO2	[mmol/l]	 16	 17	 14	
Potassium	[mmol/l]	 3.6	 3.4	 3.5	
Estimated	GFR	[ml/min/1.73m2]	 87	 99	 110	
Urine	biochemistries	
pH	 8	 8	 8	
Calcium/creatinine	 ratio	
[mmol/mmol]	 (upper	 limit	 of	
normal)	 0.20	(<0.6)**	 0.26	(<1.1)**	 4.25	(<1.4)	
Radiology	
Nephrocalcinosis	
(age	detected)	††	 yes	(10	years)	 yes	(9	years)	 yes	(2	years)	
Medullary	cysts	(age	detected)	 yes	(10	years)	 yes	(9	years)	 yes	(8	years)	
Deafness	
Age	at	diagnosis	[years]	 1	 1	 2	
Cochlear	implant	(age	inserted)	 yes	(4	years)	 yes	(4	years)	 yes	(13	years)	
*Data	at	presentation	for	patient	1.1	and	1.2	are	from	first	presentation	in	tertiary	center	in	
UAE	aged	8	and	6	years	respectively.		
†Data	at	presentation	for	patient	2.1	are	from	first	presentation	in	the	UK	age	2	years,	when	
she	was	partially	treated.	Data	from	the	initial	presentations	are	not	available.	
‡	UAE:	United	Arab	Emirates	
§	Mutations	were	homozygous	in	all	3	patients		∥	EXaC:	Exome	Aggregation	Consortium	
¶	SDS:	Standard	deviation	score	
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**Urine	 calcium/creatinine	values	pre-treatment	are	unavailable,	normocalciuria	was	 seen	
in	the	context	of	correction	of	metabolic	acidosis.		
††	The	 first	 renal	 imaging	of	patients	1.1	and	1.2	was	at	age	10	and	9	years,	 respectively.	
Nephrocalcinosis	and	cysts	may	have	been	present	earlier.	
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Figure	1	
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Figure	2	
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FIGURE	LEGENDS	
	
Figure	 1.	 Panel	 A	 and	 B	 shows	 the	 family	 pedigrees	 and	 status	 with	 respect	 to	 FOXI1	
mutation	genotype.	Squares	denote	male	family	members,	circles	female	members.	Shaded	
symbols	 denote	 affected	 members	 with	 homozygous	 mutation,	 semi-shaded	 symbols	
denote	 heterozygous	 carriers.	 Arrows	 denote	 the	 probands	 (Patient	 1.1	 in	 Family	 1	 and	
Patient	2.1	in	Family	2).	Panel	C	and	D	show	sequence	chromatograms	of	the	affected	and	
parental	 genotype.	Mutations	 are	marked	with	 an	 arrowhead.	 Panels	 E	 and	 F	 show	 renal	
ultrasound	scans	demonstrating	medullary	nephrocalcinosis	in	all	affected	and	cystic	change	
within	 the	kidneys	 in	Patient	1.1	and	2.1.	CT	volumetric	 rendering	of	 the	right	 labyrinth	 in	
Patient	2.1	revealed	dilation	of	the	endolymphatic	sac	(panel	F,	white	arrow)	compared	with	
healthy	control	(panel	F,	lower	CT	scan).		Note	the	normal	appearance	of	the	cochlea	(C)	and	
lateral	 semicircular	 canals	 (SC)	 in	 Patient	 2.1.	 Panel	 G	 depicts	 the	 secondary	 structural	
elements	of	the	Foxa3	DNA-binding	domain	(α-helices,	cylinders;	β-sheets,	arrows;	and	wing	
domains,	W1	and	W2)	above	sequence	alignments	with	FOXI1	proteins	from	various	species.		
FOXI1	L146	in	helix	2	(α2)	is	indicated	by	the	red	arrow,	and	FOXI1	R213	in	wing	2	(W2)	by	
the	 black	 arrow.	 Panel	 H	 shows	 superposition	 of	 the	 human	 FOXI1	 homology	 model	 (in	
green)	with	the	crystal	structure	of	Foxa3	(in	orange)	bound	to	DNA.	The	recognition	helix	
(α3)	of	Foxa3	is	positioned	in	the	major	groove	of	the	cognate	DNA	and	stabilized	in	part	by	
a	 3.4Å	 interaction	 between	 Foxa3	 L142	 and	 the	 sugar-phosphate	 backbone	 (Panel	 I).	
Mutation	 of	 the	 homologous	 leucine	 residue	 in	 FOXI1	 to	 phenylalanine	 (L146F;	 colored	
magenta,	panel	J)	is	predicted	to	disrupt	DNA	binding.	Panel	K	shows	a	close-up	view	of	the	
wing	2	domain	(W2)	of	Foxa3	and	FOXI1.	 	L209	 in	Foxa3	forms	a	4.3Å	 interaction	with	the	
DNA	 backbone.	 The	 structurally	 homologous	 FOXI1	 R213	 is	 predicted	 to	 facilitate	 DNA	
binding,	similar	to	the	role	of	R210,	R211	and	R214	in	W2	of	Foxa3.	Mutation	of	FOXI1	R213	
to	proline	(R213P;	colored	magenta,	panel	L)	will	destroy	the	electrostatic	 interaction	with	
DNA.	
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Figure	 2.	 Effect	 of	 FOXI1	 mutations	 on	 protein	 stability,	 promoter	 transactivation,	 DNA	
binding	and	cellular	localization.	Western	blot	analysis	of	FOXI1	protein	expression	(Panel	A)	
in	 whole	 cell	 lysates	 from	 HEK	 293T	 cells	 transfected	 with	 FOXI1	 wild	 type	 (WT),	 L146F	
mutant,	 R213P	 mutant,	 or	 empty	 vector	 (EV).	 To	 determine	 equal	 protein	 loading,	 the	
membrane	was	stripped	and	re-probed	for	b-actin.	*	indicates	incomplete	stripping	of	signal	
from	the	FOXI1	labelling.	Panel	B	demonstrates	reporter	gene	activity,	expressed	in	relative	
luciferase	 units	 (RLU),	 upon	 co-transfection	 of	 increasing	 amounts	 (15,	 30	 and	 75	 ng)	 of	
FOXI1	 expression	 plasmid	 and	 25	 ng	 of	 ATP6V0A4,	 pendrin,	 or	 AE1	 promoter	 reporter	
constructs	 in	 HEK	 293T	 cells.	 Level	 of	 significance,	 calculated	 by	 two-way	 ANOVA	 using	
GraphPad	Prism	5,	is	indicated;	**	p	<	0,01,	***	p	<	0,001.	****	p	<	0,0001.	Panel	C	shows	
EMSA	 using	 in	 vitro	 transcribed/translated	 FOXI1	 wild	 type	 (WT),	 L146F,	 or	 R213P,	 and	
empty	vector	(EV)	as	control,	and	radio-labelled	oligonucleotides	harboring	a	FOXI1	binding	
site.	 Bound	 and	 unbound	 oligonucleotides	 (oligos)	 are	 marked.	 Lower	 panel	 shows	 a	
Western	 blot	 of	 the	 transcribed/translated	 products.	 Panel	 D	 illustrates	 the	 intracellular	
localization	of	FOXI1-GFP	fusion	proteins	after	transfection	of	HEK	293T	cells	with	FOXI1	wild	
type,	L146F,	or	R213P	mutants,	or	empty	vector	(EV)	respectively.	Green	channel;	GFP	signal	
(inset	 shows	 zoom	 in	on	 single	 cell),	 red	 channel;	 nuclear	 staining	 (TO-PRO-3),	 and	merge	
channel;	all	channels	together.	Scale	bar	is	10	µm.	
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SUPPLEMENTARY	APPENDIX	
	
	
In	silico	modelling	
The	 DNA-binding	 domain	 (residues	 121-221)	 of	 human	 FOXI1	 (accession	 number	
NP_036320)	 was	 modelled	 against	 the	 crystal	 structure	 of	 rat	 Foxa3	 (hepatocyte	 nuclear	
factor-3γ/HNF-3γ))	 (PDB	 accession	 code	 1VTN)1	 	 using	 HHPred2	 	 and	Modeller3	 software.		
Homology	model	 figures	were	prepared	using	PyMOL	(http://www.pymol.org/).	Consistent	
with	protein	sequence	alignments	(Fig.	S1),	identical	results	were	obtained	using	the	crystal	
structures	 of	 FOXM1,4	 FOXO4,5	 FOXK2,6	 and	 Foxd37	 	 (Fig.	 S2).	 	 It	 should	 be	 noted	 that	
predicted	 position	 of	 the	 FOXI1	 R213	 residue	 was	 specific	 to	 the	 Foxa3	 homology	model	
since	this	region	of	the	wing	2	domain	in	the	other	structures	used	for	modelling	was	either	
not	resolved	or	captured	in	contact	with	the	DNA.		Interestingly,	a	similar	missense	mutation	
(p.R169P)	in	FOXC1	has	been	shown	to	disrupt	DNA	binding	and	transcriptional	activation.8	
Sequence	analysis	predicts	FOXC1	R169	occupies	a	homologous	position	to	FOXI1	R214,	just	
one	residue	downstream	of	FOXI	R213	(Fig.	S1),	thereby	providing	further	evidence	for	the	
functional	importance	of	this	domain.	
	
Plasmid	constructs	
Full	 length	 FOXI1	 coding	 sequence	 was	 previously	 cloned	 into	 the	 expression	 vector	
pcDNA3.1.9	 FOXI1	 was	 also	 cloned	 in-frame	 with	 GFP	 in	 the	 expression	 vector	 pEGFP-N3	
(Clontech,	USA),	 to	make	 FOXI1-GFP	 fusion	protein.	Mutant	 FOXI1	 L146F	 and	R213P	were	
generated	 by	 site-directed	 mutagenesis	 using	 Quikchange	 Lightning	 Site-directed	
mutagenesis	 kit	 (Agilent	 Technologies,	 USA)	 using	 the	 following	 primers	 (mutations	
underlined):		
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FOXI1	p.L146F	FWD	5’-ATCTGGCTGAAAGTGAGGCGCTTGTCGGGT-3’;		
FOXI1	p.L146F	REV	5’-ACCCGACAAGCGCCTCACTTTCAGCCAGAT-3’;		
FOXI1	p.R213P	FWD	5’-ATTTTCTCTTCCTTTTCCTGGGGAAATTTCCATTGTCGAAC-3’;		
FOXI1	p.R213P	REV	5’-GTTCGACAATGGAAATTTCCCCAGGAAAAGGAAGAGAAAAT-3’		
Promoter	 reporter	 constructs	 were	 previously	 generated	 by	 cloning	 promoter	 regions	 of	
ATP6V0A4,10	AE1	(SLC4A1),9	and	pendrin	(SLC26A4)	9	into	pGL3	Basic	vector	(Promega,	USA).	
The	 sequence	 of	 each	 construct	 was	 verified	 by	 Sanger	 sequencing	 performed	 by	 GATC	
Biotech	Ltd	(Germany).	
	
Cell	culture,	transfections,	and	luciferase	assay	
Human	embryonic	kidney	(HEK)	cell	line	293T	(ATCC®	CRL-3216™)	was	maintained	on	gelatin	
coated	flasks	 in	Dulbecco’s	Modified	Eagle	medium	(DMEM,	Thermo	Fisher	Scientific,	USA;	
41965-039)	 supplemented	 with	 10%	 fetal	 bovine	 serum	 (Thermo	 Fisher	 Scientific,	 USA;	
16140-071)	 and	 1	 mM	 sodium	 pyruvate	 (Thermo	 Fisher	 Scientific,	 USA;	 11360-039).	
Transient	 transfections	 were	 performed	 using	 Lipofectamine	 2000	 transfection	 reagent	
(Thermo	Fisher	Scientific,	USA;	11668-019)	according	to	manufacturer’s	protocol.		
For	 luciferase	 assays,	 cells	 90-100%	 confluence	 were	 trypsinized,	 added	 to	 a	
DNA/Lipofectamine	mix	in	Opti-MEM®	I	Reduced	Serum	Medium	(Thermo	Fisher	Scientific,	
USA;	31985-070)	and	then	plated,	in	triplicate,	with	dilution	approximately	1:1,	into	gelatin	
coated	 96-well	 plates	 (Sarstedt,	Germany;	 83.1835.300).	 Cells	were	 co-transfected	with	 0,	
15,	30	or	75	ng	of	FOXI1	expression	plasmid	and	25	ng	of	the	luciferase	promoter	constructs	
for	ATP6V0A4,	AE1	 (SLC4A1)	 or	 pendrin	 (SLC26A4).	 Renilla	 luciferase	plasmid	 (20	pg)	 pRL-
SV40	 (Promega,	 USA;	 E2231)	 was	 used	 to	 control	 for	 transfection	 efficiency.	 Empty	
pcDNA3.1	plasmid	was	used	to	equalize	the	total	amount	of	DNA	added	to	100	ng/well.	
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Two	days	after	transfection	cells	were	assayed	using	Dual-Luciferase®	Reporter	Assay	System	
(Promega,	USA;	E1910)	according	 to	manufacturer’s	protocol.	Briefly,	 culture	medium	was	
removed	and	25	µl	of	Passive	Lysis	Buffer	was	added	to	each	well.	Cells	were	then	incubated	
at	room	temperature	with	slow	rocking	for	30	minutes	where	after	20	µl	of	lysate	from	each	
well	was	transferred	to	corresponding	wells	of	a	white	96-well	plate	(Greiner,	Austria;	Cat.	
No.:	655075)	for	the	analysis,	which	was	performed	on	a	Tecan	infinite	M200	plate	reader.	
Results	were	calculated	as	the	quotient	between	values	for	luciferase	and	values	for	Renilla	
luciferase,	 all	 normalized	 to	 values	 for	 0	 ng	 FOXI1	 expression	 plasmid.	 For	 intracellular	
distribution	 analysis	 HEK	 293T	 cells,	 seeded	 in	 24-well	 plates	 on	 gelatin-coated	 glass	
coverslips,	were	 transfected	with	 500	ng/well	 of	 pEGFP-N3	plasmids	 containing	wild	 type,	
L146F	or	R213P	FOXI1	or	no	 insert	 (empty	vector).	Two	days	after	 transfection,	 cells	were	
fixed	for	15	min	in	4%	paraformaldehyde	in	PBS,	permeabilized	in	0.1%	Triton	X-100	in	PBS	
for	5	min	and	 incubated	at	 room	temperature	 for	30	min	with	 fluorescent	nuclear	marker	
TO-PRO-3	(Thermo	Fisher	Scientific,	USA;	T3605).	After	subsequent	washes	in	PBS,	coverslips	
were	mounted	with	 ProLong	 Diamond	 Antifade	Mountant	 (Thermo	 Fisher	 Scientific,	 USA;	
P36961).	 Imaging	of	GFP	and	TO-PRO-3	signals	was	performed	using	a	Zeiss	LSM500	Meta	
system.	
	
Western	blot	
HEK	293T	cells	 	were	lysed	in	RIPA	buffer	(50	mM	Tris-HCl,	pH	8.0,	1	mM	EDTA,	1%	NP-40,	
0.1%	sodium	deoxycholate,	0.1%	SDS,	150	mM	NaCl),	supplemented	with	cOmplete™,	EDTA-
free	 Protease	 Inhibitor	 Cocktail	 (Roche,	 Switzerland)	 according	 to	 the	 manufacturer’s	
recommendations.	 Proteins,	 from	 either	 cell	 lysates	 or	 in	 vitro	 translation/transcription,	
were	separated	by	SDS-PAGE	on	NuPAGE	Novex	4-12%	Bis-Tris	protein	gels	(Thermo	Fisher	
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Scientific,	 USA)	 and	 transferred	 to	 PVDF	 membrane	 (Millipore,	 USA).	 FOXI1	 protein	 was	
detected	 with	 polyclonal	 goat	 antibody	 (ab20454,	 Abcam,	 UK)	 diluted	 1:500	 in	 blocking	
buffer	 (5%	 (w/v)	 skim	 milk	 powder,	 50	 mM	 Tris-Cl,	 pH	 7.5,	 150	 mM	 NaCl,	 0.02%	 (v/v)	
Tween20)	followed	by	horseradish	peroxidase	(HRP)-coupled	polyclonal	rabbit	anti-goat	IgG	
(Dako,	Denmark)	diluted	1:2000	in	blocking	buffer.	HRP-coupled	b-actin	monoclonal	mouse	
antibody	 (ab20272,	 Abcam,	 UK),	 diluted	 1:5000	 in	 blocking	 buffer,	 was	 used	 as	 a	 loading	
control	 of	 cell	 lysates.	 HRP-coupled	 antibody	 was	 visualized	 with	 SuperSignal	 West	 Dura	
Chemiluminescent	 Substrates	 (Thermo	 Fisher	 Scientific,	 USA)	 on	 a	 LAS-4000	 Luminescent	
Image	analyzer	(FujiFilm,	Japan).	
	
Electrophoretic	mobility	shift	assay	(EMSA)	
In	vitro	transcription/translations	were	performed	according	to	the	manufacturer’s	protocol	
using	 TNT®	 T7	 Quick	 Coupled	 Transcription/Translation	 System	 (Promega,	 USA)	 and	 1	 µg	
expression	plasmid.	Oligonucleotides,	previously	shown	to	have	binding	affinity	for	wild	type	
FOXI1	protein,11	were	annealed	and	labeled	using	Klenow	polymerase	(Roche,	Switzerland)	
and	[α-32P]dCTP	(PerkinElmer,	USA).	For	each	binding	reaction	400000	CPM	of	labeled	probe	
was	incubated	with	3	µl	of	in	vitro	translated	FOXI1	protein	and	1	µg	of	poly	dI:dC	in	binding	
buffer	(5	mM	HEPES,	23%	glycerol,	1.5	mM	MgCl2,	0.2	mM	EDTA,	0.5	mM	DTT,	100	mM	KCl)	
supplemented	with	cOmplete™,	EDTA-free	Protease	 Inhibitor	Cocktail	 (Roche,	Switzerland)	
at	room	temperature	for	30	min.	To	the	reactions	Native	Tris-Glycine	Sample	buffer	(2X)	was	
added	and	samples	were	 resolved	on	Novex™	6%	Tris-Glycine	Mini	Gel	and	 run	 the	gel	at	
125	V	 in	Novex™	Tris-Glycine	Native	Running	Buffer	 (Thermo	 Fisher	 Scientific,	USA).	 After	
electrophoresis,	 the	 gel	 was	 dried	 using	 a	 Gel	 Dryer	 Model	 583	 (Bio-Rad,	 USA),	 in	
combination	with	HydroTech	Vacuum	Pump	(Bio-Rad,	USA),	for	2	h	at	80°	C	and	exposed	to	
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BAS	image	plate	(FujiFilm,	Japan).	The	BAS	image	plate	was	subsequently	scanned	using	FLA-
7000	scanner	(FujiFilm,	Japan).	
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SUPPLEMENTARY	FIGURES	
Figure	S1.	
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Figure	S2.	
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Figure	S3.	
	
	
Figure	S4.	
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Figure	S5.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	S6.	
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SUPPLEMENTARY	FIGURE	LEGENDS	
	
Figure	S1.	Panel	A	shows	the	crystal	structure	of	FOXM1	(PBD	accession	code	3G73)4	colored	
from	 N-terminal	 (blue)	 to	 C-terminal	 (red)	 domains.	 Secondary	 structural	 elements	 are	
labelled:	 α-helices	 (α1-α3);	 β-sheets	 (β1-β3);	 and	 wing	 domains	 1	 and	 2	 (W1	 and	 W2,	
respectively).	 Panel	B	 shows	a	 cartoon	 representation	of	 the	 FOXM1	DNA-binding	domain	
(colored	 as	 in	 A),	 depicting	 the	 approximate	 position	 of	 the	 structural	 elements	 within	
human	FOX	proteins	(sequences	aligned	below).	The	position	of	FOXI1	L146	in	α2	and	FOXI1	
R213	in	W2	are	highlighted	by	red	and	black	arrows,	respectively.	
		
Figure	 S2.	 Homology	 modelling	 results	 for	 FOXI1	 (in	 green)	 consistently	 identified	 FOXI1	
L146	 as	 occupying	 an	 identical	 position	 to	 functionally	 important	 leucine	 residues	
(numbered	 as	 in	 the	 reports)	 in	 the	 structures	 of	 FOXM1	 (panel	 A,	 in	 orange;	 PDB	 code	
3G73),	FOXO4	(panel	B,	in	cyan;	PDB	code	3L2C),	FOXK2	(panel	C,	in	purple;	PDB	code	2C6Y)	
and	Foxd3	(panel	D,	in	magenta;	PDB	code	2HDC).	Note	that	the	region	of	the	wing	2	domain	
(W2)	wherein	FOXI1	R213	 resides	was	not	either	not	 resolved	 in	 these	 structures	 (FOXM1	
and	FOXO4)	or	was	not	captured	interacting	with	the	target	DNA	(FOXK2	and	Foxd3).	
	
Figure	S3.	Dilatation	of	the	vestibular	aqueduct	and	the	endolymphatic	sac	contained	within.	
Shown	are	images	of	the	inner	ear	of	patient	2.1	(Panel	A	and	C	in	comparison	to	a	normal	
control	 (Panel	B	and	D).	A:	High	resolution	CT	of	 the	petrous	bones	shows	enlargement	of	
the	 vestibular	 aqueduct	 (arrow).	 B.	 The	 normal	 vestibular	 aqueduct	 is	 barely	 visible	 as	 a	
small	 linear	 hypodensity	 (arrow).	 C:	 High	 resolution	 NMR	 (T2)	 shows	 dilatation	 of	 the	
endolymphatic	 sac	 (arrow).	 D:	 The	 endolymphatic	 sac	 is	 not	 visible	 on	 the	 NMR	 in	 the	
control	due	to	its	small	size.	
	
Figure	S4.	A:	High	resolution	NMR	(T2)	shows	symmetrical	dilatation	of	the	endolymphatic	
sac	(arrows).	Note	that	the	signal	of	the	fluid	in	the	sacs	is	slightly	hypointense	to	the	signal	
in	 the	 lateral	 semicircular	 canals	 (arrowhead),	 due	 to	high	proteinaceous	 content.	 B:	High	
resolution	 CT	 of	 the	 petrous	 bones	 shows	 corresponding	 enlargement	 of	 the	 vestibular	
aqueduct	(arrows).		
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Figure	S5.	Determination	of	nuclear	versus	cytoplasmic	GFP	 in	293	cells.	Using	 ImageJ,	 the	
ratio	of	average	GFP	signal	intensity	in	the	nucleus	to	the	average	intensity	in	the	cytoplasm	
of	cells,	(n=15	per	condition),	was	calculated	based	on	square-shaped	equally	sized	regions	
of	 interest	 (ROIs).	The	results	show	that	the	ratio,	considered	a	measure	of	the	amount	of	
GFP	in	the	nucleus,	was	similarly	and	significantly	higher	for	all	three	FOXI1-GFP	constructs	
compared	to	the	empty	pEGFP-N3	plasmid	(EV)	(****	p	<	0.0001).	This	indicates	that	the	loss	
of	activation	of	FOXI1	target	genes	by	the	two	mutations	is	not	caused	by	a	redistribution	of	
the	FOXI1	protein.	Error	bars,	±sem.	
	
Figure	 S6.	 Immunofluorescent	 staining	 of	 FOXI1	 transfected	 293	 cells.	 293	 cells	 were	
transiently	transfected	with	pcDNA3.1	expression	plasmid	carrying	wild-type	FOXI1	or	either	
of	the	two	mutated	FOXI1	variants.	Empty	pcDNA3.1	was	used	as	empty	vector	control	(EV).	
Immunofluorescent	staining	with	anti-FOXI1	antibody	(Abcam,	ab20454)	showed	that	FOXI1	
in	all	 cases	was	primarily	 localized	 to	 the	nucleus.	No	endogenous	FOXI1	protein	could	be	
detected	in	empty	vector	control	(EV).	To-PRO-3	stains	nuclei.	
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